
|Videos|August 1, 2017
Dr. Lara on the Potential Role of IDO Inhibitors in the Treatment of RCC
Author(s)Primo N. Lara, MD
Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the potential role of IDO inhibitors in the treatment of patients with renal cell carcinoma.
Advertisement
Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the potential role of IDO inhibitors in the treatment of patients with renal cell carcinoma (RCC).
The advances of an IDO inhibitor such as epacadostat is that it is well tolerated, says Lara. In a phase Ib/II trial, it did not increase the toxicity of the base PD-1 inhibitor pembrolizumab (Keytruda).
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5



































